N-(2,4,6-trifluorophenyl)piperazine | 759443-28-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: N-(2,4,6-trifluorophenyl)piperazine
• 英文别名: 1-(2,4,6-triflurophenyl)piperazine；1-(2,4,6-Trifluorophenyl)piperazine
• CAS: 759443-28-2
• 化学式: C₁₀H₁₁F₃N₂
• mdl: MFCD11872817
• 分子量: 216.206
• InChiKey: VXGQMYJMEDLZLB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-(2,4,6-trifluorophenyl)piperazine 在 palladium 10% on activated carbon 、 氢气 、 potassium carbonate 、 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 4.0~20.0 ℃ 、413.7 kPa 条件下， 反应 5.5h， 生成 2-{3-(4-chlorobenzoyl)-4-[(4-(2,4,6-trifluorophenyl)piperazin-1-yl)methyl]thiophen-2-yl}-isoindole-1,3-dione
  参考文献：
  名称：

  Structure–activity relationships of 2-amino-3-aroyl-4-[(4-arylpiperazin-1-yl)methyl]thiophenes. Part 2: Probing the influence of diverse substituents at the phenyl of the arylpiperazine moiety on allosteric enhancer activity at the A1 adenosine receptor

  摘要：

  In a preliminary article, we reported the potent allosteric enhancer activity at the AI adenosine receptor of a small series of 2-amino-3-(4-chlorobenzoyl)-4[4-(aryl)piperazin-1-yl)methyl]thiophene derivatives bearing electron-withdrawing or electron-releasing groups at the para-position of the phenylpiperazine moiety. In the present study, we report the development of the compounds previously studied by modifying both the number and position of substituents on the phenylpiperazine moiety, aimed at establishing a structure-activity relationship identifying additional compounds with improved activity.The nature and the position of substituents on the phenyl ring tethered to the piperazine seemed to exert a fundamental influence on the allosteric enhancer activity, with the 3,4-difluoro 4i, 3-chloro-4-fluoro 4o, and 4-trifluoromethoxy 4ak derivatives being the most active compounds in binding (saturation and competition experiments) and functional cAMP studies. This study shows that it is also possible to obtain a good separation between allosteric enhancement and antagonistic activity at the A(1) adenosine receptor. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.11.044
• 作为产物：
  描述：

  哌嗪 、 1-溴-2,4,6-三氟苯 生成 N-(2,4,6-trifluorophenyl)piperazine
  参考文献：
  名称：

  Potent, selective, and orally active adenosine A2A receptor antagonists: Arylpiperazine derivatives of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines

  摘要：

  Antagonism of the adenosine A2A receptor offers great promise in the treatment of Parkinson's disease. Employing the known pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine A2A antagonist SCH 58261 as a starting point, we identified the potent and selective (vs. A1) antagonist 11h, orally active in the rat haloperidol-induced catalepsy model. We further optimized this lead to the methoxyethoxyethyl ether 12a (SCH 420814), which shows broad selectivity, good pharmacokinetic properties, and excellent in vivo activity.

  DOI：

  10.1016/j.bmcl.2006.11.083

文献信息

• Imidazotriazinone or imidazopyrazinone derivatives, and use thereof
  申请人：ST PHARM CO., LTD.

  公开号：US10179785B2

  公开（公告）日：2019-01-15

  The present invention relates to a novel imidazotriazinone or imidazopyrazinone derivative, a tautomer thereof, a stereoisomer thereof and their mixture, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing or treating a tankyrase-related disease, which contains the same as an active ingredient.

  本发明涉及一种新型咪唑三嗪酮或咪唑吡嗪酮衍生物、其同分异构体、其立体异构体及其混合物，或其药学上可接受的盐；以及一种用于预防或治疗与毒蕈碱相关疾病的药物组合物，其中含有相同的活性成分。
• Triamino derivatives of triazolotriazine and triazolopyrimidine as adenosine A2a receptor antagonists
  作者：Chi B. Vu、Pamela Shields、Bo Peng、Gnanasambandam Kumaravel、Xiaowei Jin、Deepali Phadke、Joy Wang、Thomas Engber、Eman Ayyub、Russell C. Petter

  DOI：10.1016/j.bmcl.2004.07.048

  日期：2004.10

  Piperazine derivatives of 2-furanyl[1,2,4]triazolo[1,5-a][1,3,5]triazine have recently been shown to be potent and selective adenosine A(2a) receptor antagonists. We now demonstrate that potent and selective A(2a) receptor antagonists could still be obtained when the arylpiperazines are separated from the triazolotriazine core structure by an ethylenediamine spacer. Selected analogs bearing this triazolotriazine or the related triazolopyrimidine core structure have been found to be orally active in a mouse catalepsy model of Parkinson's disease. (C) 2004 Elsevier Ltd. All rights reserved.
• NOVEL IMIDAZOTRIAZINONE OR IMIDAZOPYRAZINONE DERIVATIVES, AND USE THEREOF
  申请人：ST Pharm Co., Ltd.

  公开号：EP3166946A2

  公开（公告）日：2017-05-17
• USRE44205E1
  申请人：——

  公开号：USRE44205E1

  公开（公告）日：2013-05-07
• [EN] NOVEL IMIDAZOTRIAZINONE OR IMIDAZOPYRAZINONE DERIVATIVES, AND USE THEREOF<br/>[FR] NOUVEAUX DÉRIVÉS IMIDAZOTRIAZINONE OU IMIDAZOPYRAZINONE ET LEUR UTILISATION
  申请人：ST PHARM CO LTD

  公开号：WO2016006975A2

  公开（公告）日：2016-01-14

  The present invention relates to novel a imidazotriazinone or imidazopyrazinone derivative, a tautomer thereof, a stereoisomer thereof and their mixture, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing or treating a tankyrase-related disease, which contains the same as an active ingredient.